SA520420401B1 - متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 واستخداماتها (glp-1) - Google Patents
متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 واستخداماتها (glp-1) Download PDFInfo
- Publication number
- SA520420401B1 SA520420401B1 SA520420401A SA520420401A SA520420401B1 SA 520420401 B1 SA520420401 B1 SA 520420401B1 SA 520420401 A SA520420401 A SA 520420401A SA 520420401 A SA520420401 A SA 520420401A SA 520420401 B1 SA520420401 B1 SA 520420401B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- peptide
- glp
- serial
- conjugate
- amino acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662313P | 2018-04-25 | 2018-04-25 | |
| US2018029284 | 2018-04-25 | ||
| PCT/IB2019/053384 WO2019207505A1 (en) | 2018-04-25 | 2019-04-24 | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA520420401B1 true SA520420401B1 (ar) | 2023-01-26 |
Family
ID=66676857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA520420401A SA520420401B1 (ar) | 2018-04-25 | 2020-10-22 | متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 واستخداماتها (glp-1) |
Country Status (26)
| Country | Link |
|---|---|
| EP (2) | EP4640701A3 (https=) |
| JP (2) | JP7676148B2 (https=) |
| KR (2) | KR20250142942A (https=) |
| CN (2) | CN112004822B (https=) |
| AU (2) | AU2019259790B2 (https=) |
| BR (1) | BR112020021562A2 (https=) |
| CA (1) | CA3096792A1 (https=) |
| CL (1) | CL2020002718A1 (https=) |
| CO (1) | CO2020013221A2 (https=) |
| CR (1) | CR20200487A (https=) |
| DO (1) | DOP2020000192A (https=) |
| EC (1) | ECSP20067968A (https=) |
| ES (1) | ES3049134T3 (https=) |
| IL (2) | IL278197B2 (https=) |
| JO (1) | JOP20200265A1 (https=) |
| MA (1) | MA52361A (https=) |
| MX (2) | MX2020011293A (https=) |
| MY (1) | MY207588A (https=) |
| NI (1) | NI202000071A (https=) |
| PE (1) | PE20211457A1 (https=) |
| PH (1) | PH12020551659A1 (https=) |
| SA (1) | SA520420401B1 (https=) |
| SG (1) | SG11202009844SA (https=) |
| TW (1) | TWI847981B (https=) |
| UY (1) | UY38200A (https=) |
| WO (1) | WO2019207505A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190095A1 (ar) * | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
| CR20220206A (es) | 2019-11-11 | 2022-06-16 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
| MX2022006861A (es) * | 2019-12-04 | 2022-07-11 | Scripps Research Inst | Agonistas del receptor glp2 y metodos de uso. |
| JP7661478B2 (ja) | 2020-08-07 | 2025-04-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性ｎｐｙ２受容体アゴニスト |
| CN119638849A (zh) * | 2021-10-18 | 2025-03-18 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| JP2025504612A (ja) * | 2021-12-31 | 2025-02-13 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Ｇｌｐ－１及びｇｄｆ１５の融合タンパク質並びにその使用 |
| JP2025526148A (ja) | 2022-08-18 | 2025-08-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 長時間作用型ｇｌｐ－１／グルカゴン受容体アゴニスト及びｎｐｙ２受容体アゴニストを含む組合せ治療 |
| CN117327200B (zh) * | 2023-11-28 | 2024-02-09 | 西宝生物科技（上海）股份有限公司 | 一种调控糖脂代谢和抗衰老的双功能重组蛋白gik及其制备方法 |
| WO2025247862A1 (en) * | 2024-05-27 | 2025-12-04 | Numaferm Gmbh | Methods for the c-terminal modification of (poly)peptides |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ579621A (en) * | 2004-02-11 | 2011-03-31 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties |
| EA011860B1 (ru) * | 2004-03-17 | 2009-06-30 | 7ТиЭм ФАРМА А/С | Селективные агонисты рецептора y2 для терапевтического воздействия |
| CN101128487B (zh) * | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
| JP2009510999A (ja) * | 2005-07-29 | 2009-03-19 | エーエムプロテイン コーポレイション | キメラ治療剤 |
| MX2008002028A (es) * | 2005-08-11 | 2008-03-27 | Amylin Pharmaceuticals Inc | Polipeptidos hibridos con propiedades de seleccion. |
| WO2008021560A2 (en) * | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable properties |
| US8299023B2 (en) * | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
| CN104147611A (zh) * | 2009-09-30 | 2014-11-19 | 葛兰素集团有限公司 | 具有延长的半衰期的药物融合体和缀合物 |
| EP3368556B1 (en) * | 2015-10-28 | 2024-04-10 | Tufts University | Novel polypeptides with improved proteolytic stability, and methods of preparing and using same |
| JOP20190095A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y |
-
2019
- 2019-04-23 TW TW108114084A patent/TWI847981B/zh active
- 2019-04-24 AU AU2019259790A patent/AU2019259790B2/en active Active
- 2019-04-24 MX MX2020011293A patent/MX2020011293A/es unknown
- 2019-04-24 KR KR1020257031804A patent/KR20250142942A/ko active Pending
- 2019-04-24 CR CR20200487A patent/CR20200487A/es unknown
- 2019-04-24 EP EP25198247.6A patent/EP4640701A3/en active Pending
- 2019-04-24 WO PCT/IB2019/053384 patent/WO2019207505A1/en not_active Ceased
- 2019-04-24 EP EP19727508.4A patent/EP3784692B1/en active Active
- 2019-04-24 KR KR1020207033769A patent/KR102865076B1/ko active Active
- 2019-04-24 IL IL278197A patent/IL278197B2/en unknown
- 2019-04-24 JO JOP/2020/0265A patent/JOP20200265A1/ar unknown
- 2019-04-24 PE PE2020001671A patent/PE20211457A1/es unknown
- 2019-04-24 CA CA3096792A patent/CA3096792A1/en active Pending
- 2019-04-24 IL IL319050A patent/IL319050A/en unknown
- 2019-04-24 ES ES19727508T patent/ES3049134T3/es active Active
- 2019-04-24 BR BR112020021562-7A patent/BR112020021562A2/pt unknown
- 2019-04-24 MY MYPI2020005540A patent/MY207588A/en unknown
- 2019-04-24 CN CN201980028055.4A patent/CN112004822B/zh active Active
- 2019-04-24 MA MA052361A patent/MA52361A/fr unknown
- 2019-04-24 JP JP2020559562A patent/JP7676148B2/ja active Active
- 2019-04-24 SG SG11202009844SA patent/SG11202009844SA/en unknown
- 2019-04-24 CN CN202411902382.7A patent/CN119708256A/zh active Pending
- 2019-04-25 UY UY38200A patent/UY38200A/es active IP Right Grant
-
2020
- 2020-10-04 PH PH12020551659A patent/PH12020551659A1/en unknown
- 2020-10-20 CL CL2020002718A patent/CL2020002718A1/es unknown
- 2020-10-22 SA SA520420401A patent/SA520420401B1/ar unknown
- 2020-10-22 CO CONC2020/0013221A patent/CO2020013221A2/es unknown
- 2020-10-22 NI NI202000071A patent/NI202000071A/es unknown
- 2020-10-23 EC ECSENADI202067968A patent/ECSP20067968A/es unknown
- 2020-10-23 MX MX2025014917A patent/MX2025014917A/es unknown
- 2020-10-23 DO DO2020000192A patent/DOP2020000192A/es unknown
-
2023
- 2023-11-29 AU AU2023274117A patent/AU2023274117B2/en active Active
-
2025
- 2025-04-30 JP JP2025075407A patent/JP2025118735A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA520420401B1 (ar) | متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 واستخداماتها (glp-1) | |
| US11732019B2 (en) | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | |
| TWI613213B (zh) | 作為雙重ｇｌｐ１／升糖素激動劑之艾塞那肽－４衍生物 | |
| US6489295B1 (en) | Antagonists of intestinotrophic GLP-2 peptides | |
| JP2020114234A (ja) | Ｘｔｅｎ共役組成物およびそれを製造する方法 | |
| JP2020007338A (ja) | グルカゴン及びｇｌｐ−１共アゴニスト化合物 | |
| JP7164247B2 (ja) | アシル化ｇｌｐ－１誘導体 | |
| TW201441252A (zh) | 做為二重ｇｌｐ１／ｇｉｐ或三重ｇｌｐ１／ｇｉｐ／昇糖素促效劑之艾塞那肽－４衍生物 | |
| US20240117000A1 (en) | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | |
| SA515370004B1 (ar) | عوامل مساعدة مشتركة لمستقبل glp-1/ جلوكاجون، مستقرة للاستخدام الطبي | |
| HK40045710A (en) | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | |
| HK40045710B (en) | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof | |
| EA045724B1 (ru) | Циклические пептидные тирозин–тирозиновые соединения в качестве модуляторов рецепторов нейропептида y |